Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genesis Biopharma Inc Announces Resignation Of CEO-Form 8-K

Tuesday, 25 Jun 2013 11:12am EDT 

Genesis Biopharma Inc reported in its Form 8-K that on June 19, 2013, the Company entered into a Settlement Agreement and General Release of All Claims with Anthony Cataldo, the Company’s former Chief Executive Officer (Cataldo). Per the Agreement, Anthony Cataldo voluntarily resigned as the Company’s Chief Executive Officer (CEO), effective as of June 1, 2013. 

Company Quote

0.5 +6.90%
19 Dec 2014